PL1869185T3 - Koniugat zawierający białko P21 do leczenia raka - Google Patents

Koniugat zawierający białko P21 do leczenia raka

Info

Publication number
PL1869185T3
PL1869185T3 PL06726802T PL06726802T PL1869185T3 PL 1869185 T3 PL1869185 T3 PL 1869185T3 PL 06726802 T PL06726802 T PL 06726802T PL 06726802 T PL06726802 T PL 06726802T PL 1869185 T3 PL1869185 T3 PL 1869185T3
Authority
PL
Poland
Prior art keywords
protein
cancer
treatment
conjugate
region
Prior art date
Application number
PL06726802T
Other languages
English (en)
Inventor
Agamemnon Epenetos
Christina Kousparou
Original Assignee
Trojan Tech Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trojan Tech Limited filed Critical Trojan Tech Limited
Publication of PL1869185T3 publication Critical patent/PL1869185T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/005—Enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43563—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects
    • C07K14/43577—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies
    • C07K14/43581—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from insects from flies from Drosophila
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Insects & Arthropods (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Inorganic Chemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL06726802T 2005-04-14 2006-04-18 Koniugat zawierający białko P21 do leczenia raka PL1869185T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0507598A GB0507598D0 (en) 2005-04-14 2005-04-14 Composition
EP20060726802 EP1869185B1 (en) 2005-04-14 2006-04-18 Conjugate comprising p21 protein for the treatment of cancer
PCT/GB2006/001407 WO2006109092A1 (en) 2005-04-14 2006-04-18 Conjugate comprising p21 protein for the treatment of cancer

Publications (1)

Publication Number Publication Date
PL1869185T3 true PL1869185T3 (pl) 2010-10-29

Family

ID=34611144

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06726802T PL1869185T3 (pl) 2005-04-14 2006-04-18 Koniugat zawierający białko P21 do leczenia raka

Country Status (16)

Country Link
US (3) US20080287357A1 (pl)
EP (1) EP1869185B1 (pl)
JP (1) JP4955654B2 (pl)
KR (1) KR20080016798A (pl)
CN (1) CN101194017B (pl)
AT (1) ATE458819T1 (pl)
AU (1) AU2006235742B2 (pl)
CA (1) CA2604536A1 (pl)
DE (1) DE602006012463D1 (pl)
DK (1) DK1869185T3 (pl)
ES (1) ES2343972T3 (pl)
GB (1) GB0507598D0 (pl)
PL (1) PL1869185T3 (pl)
PT (1) PT1869185E (pl)
SI (1) SI1869185T1 (pl)
WO (1) WO2006109092A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014310360B2 (en) 2013-06-11 2019-10-24 PPL (BVI) Limited Structure, manufacturing and uses of human-derived cell-permeable peptides conjugated with specific biologically active cargo peptides
JP7054397B2 (ja) * 2016-06-27 2022-04-13 ジュノー セラピューティクス インコーポレイテッド Ｍｈｃ－ｅ拘束性エピトープ、結合分子ならびに関連する方法および使用
CN110511273B (zh) * 2019-07-12 2021-06-01 福州市皮肤病防治院 一种细胞穿膜多肽的制备方法及其应用
CN111471095B (zh) * 2020-01-15 2021-12-21 上海众启生物科技有限公司 用于阿尔茨海默症自身抗体检测的含jmjd2d蛋白片段的组合物
GB202019864D0 (en) 2020-12-16 2021-01-27 Anastasis Biotec Ltd Improved cell-penetrating peptides and fusion proteins
CN112961865B (zh) * 2021-02-22 2023-06-02 广西大学 一种利用基因编辑鸡生物反应器表达的重组曲妥珠单抗及应用
TW202323269A (zh) * 2021-12-08 2023-06-16 荷蘭商菲林公司 方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372249B1 (en) * 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US6495526B2 (en) * 1996-01-23 2002-12-17 Gpc Biotech, Inc. Inhibitors of cell-cycle progression and uses related thereto
AU3389700A (en) * 1999-03-01 2000-09-21 Cell Genesys, Inc. Anti-neoplastic compositions and uses thereof
GB0003284D0 (en) * 2000-02-15 2000-04-05 Secr Defence Brit Anti-viral therapy
IL151910A0 (en) * 2000-04-12 2003-04-10 Implyx Ltd Compositions for drug delivery

Also Published As

Publication number Publication date
SI1869185T1 (sl) 2010-09-30
ATE458819T1 (de) 2010-03-15
US20160068582A1 (en) 2016-03-10
JP2008535512A (ja) 2008-09-04
PT1869185E (pt) 2010-05-28
CN101194017A (zh) 2008-06-04
ES2343972T3 (es) 2010-08-13
US20110021441A1 (en) 2011-01-27
US20080287357A1 (en) 2008-11-20
AU2006235742B2 (en) 2011-07-14
WO2006109092A1 (en) 2006-10-19
DK1869185T3 (da) 2010-06-21
EP1869185A1 (en) 2007-12-26
KR20080016798A (ko) 2008-02-22
CN101194017B (zh) 2013-08-28
CA2604536A1 (en) 2006-10-19
US9145446B2 (en) 2015-09-29
JP4955654B2 (ja) 2012-06-20
GB0507598D0 (en) 2005-05-18
EP1869185B1 (en) 2010-02-24
AU2006235742A1 (en) 2006-10-19
DE602006012463D1 (de) 2010-04-08
US10259852B2 (en) 2019-04-16

Similar Documents

Publication Publication Date Title
UA105210C2 (ru) Противораковая вакцина и ее применение
UA94734C2 (ru) ТЕРАПЕВТИЧЕСКОЕ АНТИТЕЛО, КОТОРОЕ СВЯЗЫВАЕТСЯ С b-АМИЛОИДНЫМ ПЕПТИДОМ
TW200716646A (en) (S)-N-methylnaltrexone
IL184617A0 (en) Dr5 antibodies and uses thereof
MXPA05008406A (es) Compuestos de amida tri(ciclo)-sustituida.
MX2011009281A (es) Conjugados de anticuerpo farmaco (adc) que enlazan a proteinas 24p4c12.
WO2007050784A3 (en) Fixed ratio drug combination treatments for solid tumors
MX272108B (es) Heterociclos sustituidos.
CY1112184T1 (el) Πυριδοξαμινη για χρηση στην αγωγη της διαβητικης nεφροπαθειας στο διαβητη τυπου ii
UA99601C2 (ru) Применение антитела к cd151 для лечения первичных опухолей
EP2175879A4 (en) TREATMENT OF DISEASES ASSOCIATED WITH PRION PROTEIN
EA200602047A1 (ru) Сульфонилэтилфосфородиамидаты, предназначенные для применения при лечении рака
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
WO2007047608A3 (en) Fibrin targeted therapeutics
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
EA200970353A1 (ru) Комбинированное лекарственное средство
SI1869185T1 (sl) Konjugat ki obsega protein P za zdravljenje raka
MX2008014247A (es) Extracto acuoso de hojas de tabaco, usos del mismo en el tratamiento de dependencia.
WO2007056301A3 (en) Antibody therapy for treatment of diseases associated with gluten intolerance
WO2005053728A3 (de) Mit adipositas assoziierte proteine und deren verwendung in therapie und diagnostik
WO2005048822A3 (en) Antibodies and/or conjugates thereof which bind to the amino terminal fragment of urokinase, compositions and uses thereof
MXPA05013121A (es) Derivados de indol con efecto de induccion de apoptosis.
WO2007007152A3 (en) Anti-madcam antibodies to treat metastatic cancers and chloroma
IL191690A0 (en) Therapy of malignant neoplasias
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases